TY - JOUR
T1 - Slowed progression
T2 - The utility of Test to Treat initiatives in improving the neglected inequities of COVID-19 among racially/ethnically minoritized groups
AU - Abdul-Mutakabbir, Jacinda C.
AU - Tillman, Frank
AU - Marcelin, Jasmine R.
AU - Saunders, Ila M.
AU - Arya, Vibhuti
N1 - Publisher Copyright:
© 2022 American Pharmacists Association®
PY - 2023/1/1
Y1 - 2023/1/1
N2 - In the United States, coronavirus disease 2019 (COVID-19) has resulted in more than 95 million infections and 1 million deaths (as of September 2022), with individuals of racially/ethnically minoritized groups being disproportionately represented among these numbers. Despite the apparent pandemic fatigue in many communities, systemic and structural racism continue to place racially/ethnically minoritized groups at a disadvantage for overcoming the virus, especially as it relates to receiving vaccinations and COVID-19 targeted therapeutics. Test to Treat programs have the potential to mitigate these disparities by rapidly identifying the presence of a COVID-19 infection and readily offering treatment options. Nonetheless, Test to Treat programs must be optimized to adequately address the limitations to care within racially/ethnically minoritized communities.
AB - In the United States, coronavirus disease 2019 (COVID-19) has resulted in more than 95 million infections and 1 million deaths (as of September 2022), with individuals of racially/ethnically minoritized groups being disproportionately represented among these numbers. Despite the apparent pandemic fatigue in many communities, systemic and structural racism continue to place racially/ethnically minoritized groups at a disadvantage for overcoming the virus, especially as it relates to receiving vaccinations and COVID-19 targeted therapeutics. Test to Treat programs have the potential to mitigate these disparities by rapidly identifying the presence of a COVID-19 infection and readily offering treatment options. Nonetheless, Test to Treat programs must be optimized to adequately address the limitations to care within racially/ethnically minoritized communities.
UR - http://www.scopus.com/inward/record.url?scp=85143280893&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143280893&partnerID=8YFLogxK
U2 - 10.1016/j.japh.2022.10.025
DO - 10.1016/j.japh.2022.10.025
M3 - Comment/debate
C2 - 36470731
AN - SCOPUS:85143280893
SN - 1544-3191
VL - 63
SP - 424
EP - 429
JO - Journal of the American Pharmacists Association
JF - Journal of the American Pharmacists Association
IS - 1
ER -